Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -45% Improvement Relative Risk ICU admission -8% ARDS -250% Hospitalization time -10% c19early.org/cp Jalili et al. Conv. Plasma for COVID-19 RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 120 patients in Iran Higher mortality (p=0.38) and ARDS (p=0.16), not stat. sig. Jalili et al., Tanaffos 21:1 Favors conv. plasma Favors control
Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial
Jalili et al., Tanaffos 21:1
Jalili et al., Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical.., Tanaffos 21:1
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 120 hospitalized patients in Iran, showing no significant differences with convalescent plasma treatment.
risk of death, 45.5% higher, RR 1.45, p = 0.38, treatment 16 of 60 (26.7%), control 11 of 60 (18.3%).
risk of ICU admission, 8.0% higher, RR 1.08, p = 0.85, treatment 27 of 60 (45.0%), control 25 of 60 (41.7%).
risk of ARDS, 250.0% higher, RR 3.50, p = 0.16, treatment 7 of 60 (11.7%), control 2 of 60 (3.3%).
hospitalization time, 9.9% higher, relative time 1.10, p = 0.39, treatment 60, control 60.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Jalili et al., 1 Jan 2022, Randomized Controlled Trial, Iran, peer-reviewed, 15 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit